Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations
Authors:
- Sigurd Broesby‐OlsenSBSigurd Broesby‐Olsen
- Charlotte Gotthard MortzCMCharlotte Gotthard Mortz
- Frank SiebenhaarFSFrank Siebenhaar
- Thomas Kielsgaard KristensenTKThomas Kielsgaard Kristensen
- Carsten Bindslev‐JensenCBCarsten Bindslev‐Jensen
- Mastocytosis Centre Odense University Hospital (MastOUH)M(Mastocytosis Centre Odense University Hospital (MastOUH)
Abstract
Background: Patients with systemic mastocytosis (SM) may suffer from mast cell (MC) mediator‐related symptoms insufficiently controlled by conventional therapy. Omalizumab is an established treatment in other MC‐driven diseases, but experiences in SM are limited.Objective: To assess the efficacy and safety of omalizumab in SM.Methods: In our patient cohort, we evaluated all SM patients treated with omalizumab. A physician global assessment of type and severity of symptoms was performed at baseline, at 3 and 6 months and at latest follow‐up. Quality of life was assessed by visual analogue scale. S‐tryptase and KIT D816V allele burden were monitored.Results: A total of 14 adult SM patients (10 ISM, 2 BMM, 1 SSM, and 1 ASM‐AHN) received omalizumab with a median duration of 17 months (range: 1‐73 months). One patient was excluded due to concomitant cytoreductive therapy. In the remaining 13 patients, we observed a significant reduction in symptoms, with complete symptom control in five (38.5%), major response in three (23.1%), and a partial response in three (23.1%) patients, whereas two patients (15.4%) withdrew due to subjective side‐effects at first dose. The treatment was most effective for recurrent anaphylaxis and skin symptoms, less for gastrointestinal, musculoskeletal, and neuropsychiatric symptoms. Patient‐reported quality of life showed significant improvement. No significant changes in s‐tryptase/KIT D816V allele burden were observed. No severe adverse events were recorded.Conclusions: Omalizumab appears to be a promising treatment option in SM, effectively preventing anaphylaxis and improving chronic MC mediator‐related symptoms, insufficiently controlled by conventional therapy. Controlled studies are needed to substantiate findings.Keywords
This publication has 23 references indexed in Scilit:
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Mast Cells, Mastocytosis, and Related DisordersNew England Journal of Medicine, 2015
- Treatment Strategies in MastocytosisImmunology and Allergy Clinics of North America, 2014
- Epidemiology of systemic mastocytosis in DenmarkBritish Journal of Haematology, 2014
- Short-term omalizumab treatment in an adolescent with cutaneous mastocytosisAnnals of Allergy, Asthma & Immunology, 2013
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaNew England Journal of Medicine, 2013
- Mast cells and mastocytosisBlood, 2008
- Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapyJournal of Allergy and Clinical Immunology, 2007
- Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosisJournal of Allergy and Clinical Immunology, 2007
- Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response CriteriaEuropean Journal of Clinical Investigation, 2007